Pharma's Almanac: Nice Insight's Content Community

FDA Approval

FDA Approval

CDMO

UCB Announces FDA Approvals for BIMZELX for Psoriatic Arthritis, Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB

Clinical Result

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in Clinical Oncology

Actinium Pharmaceuticals, Inc.

Expansion

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Benedikt von Braunmühl; Tom Roberts

Rentschler Biopharma SE

FDA Approval

Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol

Lamassu Biotech

FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Column: Clinical Trials

CAR-T Study Shines New Spotlight on Clinical Trials Representation

David Alvaro, Ph.D.

Pharma's Almanac

Column: New Drug Watch

New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes

David Alvaro, Ph.D.

Pharma's Almanac

Column: New Drug Watch

Alzheimer Drug Still Controversial

Cynthia A. Challener, Ph.D.

Pharma's Almanac

COVID-19 Vaccine

FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

Brand Institute

FDA Approval

FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease

Biogen

FDA Approval

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Bristol-Myers Squibb

FDA Approval

Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis

Novartis

FDA Approval

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

Blueprint Medicines

Antibodies

Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

Eli Lilly and Company

FDA Approval

FDA Approves First Treatment for Ebola Virus

U.S. Food & Drug Administration

Opioid

Trevena Announces FDA Approval of OLINVYK Injection

Trevena

FDA Approval

FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

GSK in Oncology

COVID-19 Treatment

Common FDA-Approved Drug May Effectively Neutralize Virus That Causes COVID-19

Rensselaer Polytechnic Institute

Nice Insight Overview

Drug Approval Trends: Significant Acceleration in Recent Years

Nigel Walker

Nice Insight

FDA Approval

FDA Approves First-Of-Its-Kind Percep PC Neurostimulator with BrainSense Technology

Medtronic

CDMO

UCB Announces FDA Approvals for BIMZELX for Psoriatic Arthritis, Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB

Clinical Result

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in Clinical Oncology

Actinium Pharmaceuticals, Inc.

Expansion

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Benedikt von Braunmühl; Tom Roberts

Rentschler Biopharma SE

FDA Approval

Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol

Lamassu Biotech